Zusammenfassung
Bei der primären Radiochemotherapie (RCT) von lokal fortgeschrittenen Kopf-Hals-Tumoren stehen sich 2 mögliche Vorgehensweisen gegenüber und sind Gegenstand der aktuellen Studien: die konkomitante und die sequenzielle RCT. Beim jährlichen Treffen der American Society of Clinical Oncology (ASCO) wurden auch 2014 Studien zur primären, nichtchirurgischen Therapie lokal fortgeschrittener Kopf-Hals-Tumoren vorgestellt. Eine Auswahl wird in diesem Beitrag besprochen, u. a. wird auf die cisplatinbasierte RCT als Standardtherapie für lokal fortgeschrittene Kopf-Hals-Tumoren, alternative Substanzen für Cisplatin, die Kombination mit Targettherapeutika, den Einsatz des epidermalen Wachstumsfaktorrezeptor(EGFR)-Antikörpers Cetuximab und auf den Vergleich der sequenziellen Therapie mit der konkomitanten RCT eingegangen. Darunter wird auch eine erstmalig vollständig rekrutierte Phase-III-Studie zur Induktionschemotherapie vorgestellt.
Abstract
The two available options for primary radiochemotherapy (RCT) of locally advanced head and neck squamous cell carcinoma are discussed in the current study: concomitant and sequential RCT. At the annual meeting of the American Society of Clinical Oncology (ASCO) 2014, results of current trials on the primary nonsurgical therapy of locally advanced head and neck tumors were presented. A selection of the most important trials will be summarized in this article. Studies including cisplatin-based RCT as standard therapy for locally advanced head and neck tumors, alternatives for cisplatin, combination with targeted therapy, application of the epidermal growth factor receptor (EGFR) antibody cetuximab and the comparison of concomitant and sequential RCT are discussed. The first completely recruited phase III trial comparing concomitant and sequential RCT will also be presented.
Literatur
Adkins D, Ley J, Nussenbaum B et al (2011) Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 29(Suppl):abstr 5560
Ali EM, Hasan E, Elyamany A et al (2014) Gemcitabine versus cisplatin concomitant with radiotherapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 32(Suppl):abstr e17039
Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29(Suppl):abstr 5500
Barni S, Coinu A, Borgonovo K et al (2014) Cisplatin versus Cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: a meta-analysis of published trials. J Clin Oncol 32:5s (Suppl):abstr 6014
Bauman JE, Gooding WE, Clump DA (2014) Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAB) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). J Clin Oncol 32:5s (Suppl):abstr TPS6104
Bonner JA, Harari PM, Giralt J (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28
Budach W, Boelke E, Kammers K et al (2014) Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): a meta-analysis of randomized trials. J Clin Oncol 32:5s (Suppl):abstr 6012
Cmelak A, Li S, Marur S et al (2014) E1308: reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol 32:5s (Suppl):abstr LBA6006
Cohen E, Karrison T, Kocherginsky M (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30(Suppl):abstr 5500
Dietz A, Flentje M, Hagen R et al (2014) Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-Fluorouracil (f) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): first results of the phase II randomized DeLOS-II study. J Clin Oncol 32:5s (Suppl):abstr 6016
Forastiere A, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098
Forastiere A, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852
Ghi MG, Paccagnella A, Ferrari D et al (2014) Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 32:5s (Suppl):abstr 6004
Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264
Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25(1):216–225
Knecht R (2014) Induction chemotherapy (ICT) followed by radiochemotherapy (RCT) versus radiochemotherapy alone as treatment in advanced laryngeal (LC)/hypopharyngeal cancer (HC): phase IIb. J Clin Oncol 32:5s (Suppl):abstr 6015
Ley JC, Nussenbaum B, Diaz J et al (2014) Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF + Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 32:5s (Suppl):abstr 6013
Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159
Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522
Pignon JP, Maître A le, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14
Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin und fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715
Rosenthal I, Harari PM, Giralt J (2014) Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 32:5s (Suppl):abstr 6001
Savvides P, Ayyappan S, Yao M et al (2014) Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 32:5s (Suppl):abstr 6070
Vermorken JB, Remenar E, Herpen C van et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704
Weidhaas JB, Harris J, Axelrod R et al (2014) The KRAS-variant and cetuximab response in RTOG 0522. J Clin Oncol 32:5s (Suppl):abstr 6000
Einhaltung ethischer Richtlinien
Interessenkonflikt. A. Gliese und C.-J. Busch geben an, dass kein Interessenkonflikt besteht. R. Knecht ist Mitglied des Advisory Boards von Merck Serono, Sanofi Aventis, Boehringer Ingelheim und Bayer Healthcare Leverkusen. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gliese, A., Busch, CJ. & Knecht, R. Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren. HNO 62, 781–786 (2014). https://doi.org/10.1007/s00106-014-2926-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-014-2926-1
Schlüsselwörter
- Plattenepithelkarzinome
- Cetuximab
- Konkomitante Radiochemotherapie
- Induktionschemotherapie
- Targettherapie